Mereo BioPharma Group plc (MREO)
| Previous close | 3.1100 |
| Open | 3.1600 |
| Bid | 3.1900 x 600 |
| Ask | 3.2600 x 600 |
| Day's range | 3.1400 - 3.2300 |
| 52-week range | 0.9200 - 4.3600 |
| Volume | |
| Avg. volume | 1,248,262 |
| Market cap | 453.079M |
| Beta (5Y monthly) | 0.78 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.2000 |
| Earnings date | 29 Mar 2024 - 02 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.26 |
ZacksMEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for MEREO BIOPHARMA (MREO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
GlobeNewswireMereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
LONDON, April 03, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 10:15am ET / 03:15pm BST. A live audio webcast of the presentation can be accessed through the Investors section of the Compa
GuruFocus.comMereo BioPharma Group PLC (MREO) Announces Full Year 2023 Financial Results
Setrusumab and Alvelestat Progress as Company Prepares for Transformative 2024
